zorevunersen Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for zorevunersen comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Epilepsies, Myoclonic. Most recent publication: Zorevunersen in Children and Adolescents with Dravet Syndrome., N Engl J Med, 2026.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- Zorevunersen in Children and Adolescents with Dravet Syndrome.Laux L, Sullivan J, Perry MS, et al. · N Engl J Med · 2026
Publications by year
2026–2026: 1 publications.
2026
1
Publications by indication
Epilepsies, Myoclonic (1)
- Zorevunersen in Children and Adolescents with Dravet Syndrome.
Publications by journal
- N Engl J Med1 paper
All zorevunersen publications (1)
2026 (1 paper)
- Zorevunersen in Children and Adolescents with Dravet Syndrome.Laux L, Sullivan J, Perry MS, et al. · N Engl J Med · 2026 · Derived
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Tue, 26 May 2026 18:22:19 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).